Overview
Juvisé Pharmaceuticals is a multinational supplier of ethical medicines across several medical fields, including oncology, cardiology, neurology, psychiatry, and rheumatology. It serves healthcare providers, hospitals, and medical professionals in international markets. Its products, such as Sintrom, Digoxin, Entumin, Insidon, Extovyl, and Lumirelax, are prescription medicines used to treat conditions like breast and prostate cancer, thromboembolic heart diseases, deep vein thrombosis, pulmonary embolism, high blood pressure, schizophrenia, bipolar and anxiety disorders, chronic depression, vertigo, and muscle contractures. The company emphasizes an integrated, reliable approach and high-quality standards, guiding its operations and supply across regions. Its goal is to offer dependable, high-quality ethical medicines to meet the needs of clinicians and patients worldwide, supported by a broad international presence and a collaborative distribution network.
Work here?Claim your company
Simplify's take
What believers are saying
- Juvisé closed a €550 million refinancing in February 2026, extending acquisition firepower.
- Ponvory rights outside the United States and Canada provide patented multiple-sclerosis revenue through 2035.
- The company relocates 95% of production to Europe, improving supply control and resilience.
What critics are saying
- PONVORY patents face Teva and STADA opposition; EPO dismissed appeals on October 12, 2026.
- Heavy debt from the €550 million refinancing increases pressure if acquisitions underperform.
- A failed PONVORY commercialization would cripple growth and expose Juvisé’s acquisition-led model.
What makes Juvisé Pharmaceuticals unique
- Juvisé sells essential off-patent and patent-protected medicines in 80-plus countries.
- Its 2026 Hayfin refinancing funded growth M&A and €150 million capex notes.
- The 2026 CEO transition preserves founder Frédéric Mascha’s control over strategy and acquisitions.
Help us improve and share your feedback! Did you find this helpful?